Literature DB >> 15341874

Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor.

Luigi Ascione1, Mario De Michele, Maria Accadia, Pasquale Spadaro, Salvatore Rumolo, Bernardino Tuccillo.   

Abstract

We report a case of idiopathic hypereosinophilic syndrome in a young man, who showed symptoms and electrocardiographic findings mimicking an acute coronary syndrome. Two-dimensional echocardiography, together with laboratory data, allowed us to make the diagnosis and to start a treatment with imatinib mesylate, a 2-phenylamonopyrimidine-based tyrosine kinase inhibitor, which reversed the cardiac abnormalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341874     DOI: 10.1016/j.euje.2004.02.006

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  4 in total

1.  Successful treatment of cardiac manifestation of eosinophilic leukemia.

Authors:  Alexander Hess; Grigorios Korosoglou; Wolfgang Rottbauer; Hugo A Katus; Derliz Mereles
Journal:  Clin Res Cardiol       Date:  2010-03-10       Impact factor: 5.460

2.  Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Authors:  Maryam Arefi; Juan L García; M Montserrat Briz; Felipe de Arriba; Juan N Rodríguez; Guillermo Martín-Núñez; Joaquín Martínez; Javier López; Julio G Suárez; M José Moreno; M Angeles Merino; Norma C Gutiérrez; Jesús Marίa Hernández-Rivas
Journal:  Int J Hematol       Date:  2012-07-18       Impact factor: 2.490

Review 3.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616

4.  Mitral valve destruction by Hodgkin's lymphoma-associated Loefler endocarditis.

Authors:  Sergey Yalonetsky; David Mishaly; Ayelet Ben-Barak; Avraham Lorber
Journal:  Pediatr Cardiol       Date:  2007-11-15       Impact factor: 1.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.